190 related articles for article (PubMed ID: 33226796)
1. Copper(II) Binding to PBT2 Differs from That of Other 8-Hydroxyquinoline Chelators: Implications for the Treatment of Neurodegenerative Protein Misfolding Diseases.
Summers KL; Roseman GP; Sopasis GJ; Millhauser GL; Harris HH; Pickering IJ; George GN
Inorg Chem; 2020 Dec; 59(23):17519-17534. PubMed ID: 33226796
[TBL] [Abstract][Full Text] [Related]
2. Alzheimer's Drug PBT2 Interacts with the Amyloid β 1-42 Peptide Differently than Other 8-Hydroxyquinoline Chelating Drugs.
Summers KL; Roseman G; Schilling KM; Dolgova NV; Pushie MJ; Sokaras D; Kroll T; Harris HH; Millhauser GL; Pickering IJ; George GN
Inorg Chem; 2022 Sep; 61(37):14626-14640. PubMed ID: 36073854
[TBL] [Abstract][Full Text] [Related]
3. The solution structure of the copper clioquinol complex.
Pushie MJ; Nienaber KH; Summers KL; Cotelesage JJ; Ponomarenko O; Nichol HK; Pickering IJ; George GN
J Inorg Biochem; 2014 Apr; 133():50-6. PubMed ID: 24503514
[TBL] [Abstract][Full Text] [Related]
4. Simple and mixed complexes of copper(II) with 8-hydroxyquinoline derivatives and amino acids: Characterization in solution and potential biological implications.
Sgarlata C; Arena G; Bonomo RP; Giuffrida A; Tabbì G
J Inorg Biochem; 2018 Mar; 180():89-100. PubMed ID: 29247871
[TBL] [Abstract][Full Text] [Related]
5. Chelator PBT2 Forms a Ternary Cu
Drew SC
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298218
[TBL] [Abstract][Full Text] [Related]
6. Solution Chemistry of Copper(II) Binding to Substituted 8-Hydroxyquinolines.
Summers KL; Pushie MJ; Sopasis GJ; James AK; Dolgova NV; Sokaras D; Kroll T; Harris HH; Pickering IJ; George GN
Inorg Chem; 2020 Oct; 59(19):13858-13874. PubMed ID: 32936627
[TBL] [Abstract][Full Text] [Related]
7. Metal protein attenuating compounds for the treatment of Alzheimer's dementia.
Sampson EL; Jenagaratnam L; McShane R
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD005380. PubMed ID: 24563468
[TBL] [Abstract][Full Text] [Related]
8. Metal protein attenuating compounds for the treatment of Alzheimer's dementia.
Sampson EL; Jenagaratnam L; McShane R
Cochrane Database Syst Rev; 2012 May; 5(5):CD005380. PubMed ID: 22592705
[TBL] [Abstract][Full Text] [Related]
9. Clioquinol, a drug for Alzheimer's disease specifically interfering with brain metal metabolism: structural characterization of its zinc(II) and copper(II) complexes.
Di Vaira M; Bazzicalupi C; Orioli P; Messori L; Bruni B; Zatta P
Inorg Chem; 2004 Jun; 43(13):3795-7. PubMed ID: 15206857
[TBL] [Abstract][Full Text] [Related]
10. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
[TBL] [Abstract][Full Text] [Related]
11. Metal Ions in Alzheimer's Disease: A Key Role or Not?
Liu Y; Nguyen M; Robert A; Meunier B
Acc Chem Res; 2019 Jul; 52(7):2026-2035. PubMed ID: 31274278
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective copper bis(thiosemicarbazonato) complexes promote neurite elongation.
Bica L; Liddell JR; Donnelly PS; Duncan C; Caragounis A; Volitakis I; Paterson BM; Cappai R; Grubman A; Camakaris J; Crouch PJ; White AR
PLoS One; 2014; 9(2):e90070. PubMed ID: 24587210
[TBL] [Abstract][Full Text] [Related]
13. Stoichiometry and conditional stability constants of Cu(II) or Zn(II) clioquinol complexes; implications for Alzheimer's and Huntington's disease therapy.
Ferrada E; Arancibia V; Loeb B; Norambuena E; Olea-Azar C; Huidobro-Toro JP
Neurotoxicology; 2007 May; 28(3):445-9. PubMed ID: 17382398
[TBL] [Abstract][Full Text] [Related]
14. Metal Protein-Attenuating Compound for PET Neuroimaging: Synthesis and Preclinical Evaluation of [
Krishnan HS; Bernard-Gauthier V; Placzek MS; Dahl K; Narayanaswami V; Livni E; Chen Z; Yang J; Collier TL; Ran C; Hooker JM; Liang SH; Vasdev N
Mol Pharm; 2018 Feb; 15(2):695-702. PubMed ID: 29298483
[TBL] [Abstract][Full Text] [Related]
15. Preparation and study of new poly-8-hydroxyquinoline chelators for an anti-Alzheimer strategy.
Deraeve C; Boldron C; Maraval A; Mazarguil H; Gornitzka H; Vendier L; Pitié M; Meunier B
Chemistry; 2008; 14(2):682-96. PubMed ID: 17969218
[TBL] [Abstract][Full Text] [Related]
16. PBT2 acts through a different mechanism of action than other 8-hydroxyquinolines: an X-ray fluorescence imaging study.
Summers KL; Dolgova NV; Gagnon KB; Sopasis GJ; James AK; Lai B; Sylvain NJ; Harris HH; Nichol HK; George GN; Pickering IJ
Metallomics; 2020 Dec; 12(12):1979-1994. PubMed ID: 33169753
[TBL] [Abstract][Full Text] [Related]
17. Transfer of Copper from an Amyloid to a Natural Copper-Carrier Peptide with a Specific Mediating Ligand.
Nguyen M; Bijani C; Martins N; Meunier B; Robert A
Chemistry; 2015 Nov; 21(47):17085-90. PubMed ID: 26420347
[TBL] [Abstract][Full Text] [Related]
18. The Alzheimer's therapeutic PBT2 promotes amyloid-β degradation and GSK3 phosphorylation via a metal chaperone activity.
Crouch PJ; Savva MS; Hung LW; Donnelly PS; Mot AI; Parker SJ; Greenough MA; Volitakis I; Adlard PA; Cherny RA; Masters CL; Bush AI; Barnham KJ; White AR
J Neurochem; 2011 Oct; 119(1):220-30. PubMed ID: 21797865
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, characterization and pharmacological evaluation of quinoline derivatives and their complexes with copper(ΙΙ) in in vitro cell models of Alzheimer's disease.
Pavlidis N; Kofinas A; Papanikolaou MG; Miras HN; Drouza C; Kalampounias AG; Kabanos TA; Konstandi M; Leondaritis G
J Inorg Biochem; 2021 Apr; 217():111393. PubMed ID: 33610031
[TBL] [Abstract][Full Text] [Related]
20. Regulation of copper and iron homeostasis by metal chelators: a possible chemotherapy for Alzheimer's disease.
Robert A; Liu Y; Nguyen M; Meunier B
Acc Chem Res; 2015 May; 48(5):1332-9. PubMed ID: 25946460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
